Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMYNASDAQ:GUTSNASDAQ:ICADNASDAQ:OBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$1.04$1.18$0.86▼$1.80$28.33M-2.52236,502 shs140,259 shsGUTSFractyl Health$1.95+8.3%$1.38$0.87▼$7.43$95.51M0.1309,840 shs201,379 shsICADiCAD$3.79+1.6%$2.90$1.18▼$4.02$104.12M1.35407,427 shs439,254 shsOBIOOrchestra BioMed$2.82+3.7%$3.04$2.37▼$8.87$108.04M0.67165,567 shs174,835 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys0.00%0.00%-15.45%-34.18%-18.75%GUTSFractyl Health0.00%-15.09%+42.86%+24.14%-75.87%ICADiCAD0.00%-6.28%+13.72%+46.27%+136.08%OBIOOrchestra BioMed0.00%-6.85%-2.16%-41.13%-48.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFEMYFemasys2.7098 of 5 stars3.53.00.00.02.62.50.6GUTSFractyl Health1.8901 of 5 stars3.52.00.00.02.71.70.0ICADiCAD0.4503 of 5 stars0.03.00.00.02.60.80.0OBIOOrchestra BioMed2.1136 of 5 stars4.63.00.00.00.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$8.67733.33% UpsideGUTSFractyl Health 3.00Buy$11.00464.10% UpsideICADiCAD 2.00HoldN/AN/AOBIOOrchestra BioMed 3.20Buy$14.20403.55% UpsideCurrent Analyst Ratings BreakdownLatest FEMY, OBIO, ICAD, and GUTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/17/2025ICADiCADLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/16/2025ICADiCADBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/16/2025ICADiCADCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025GUTSFractyl HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.70M16.67N/AN/A$0.85 per share1.22GUTSFractyl Health$60K1,591.75N/AN/AN/A∞ICADiCAD$19.53M5.33N/AN/A$1.27 per share2.98OBIOOrchestra BioMed$2.89M37.44N/AN/A$1.90 per share1.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$14.25M-$0.91N/AN/AN/A-1,435.77%-141.49%-82.30%8/14/2025 (Estimated)GUTSFractyl Health-$77.09M-$1.85N/AN/AN/A-64,849.48%N/A-57.21%8/13/2025 (Estimated)ICADiCAD-$4.85M-$0.19N/A∞N/A-17.81%-15.65%-12.52%8/11/2025 (Estimated)OBIOOrchestra BioMed-$49.12M-$1.78N/AN/AN/A-2,179.33%-107.04%-70.88%N/ALatest FEMY, OBIO, ICAD, and GUTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/13/2025Q1 2025ICADiCAD-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 million3/27/2025Q4 2024FEMYFemasys-$0.25-$0.23+$0.02-$0.23$1.66 million$0.58 million3/19/2025Q4 2024ICADiCAD-$0.0525-$0.03+$0.0225-$0.03$4.72 million$5.41 million3/3/2025Q4 2024GUTSFractyl Health-$0.44-$0.52-$0.08-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/AICADiCADN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.863.943.26GUTSFractyl Health0.605.585.57ICADiCADN/A4.023.91OBIOOrchestra BioMedN/A4.234.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%GUTSFractyl HealthN/AICADiCAD24.61%OBIOOrchestra BioMed53.55%Insider OwnershipCompanyInsider OwnershipFEMYFemasys12.32%GUTSFractyl HealthN/AICADiCAD10.29%OBIOOrchestra BioMed8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3027.24 million20.08 millionNot OptionableGUTSFractyl Health10248.98 millionN/AN/AICADiCAD14027.47 million23.81 millionOptionableOBIOOrchestra BioMed438.31 million35.47 millionNot OptionableFEMY, OBIO, ICAD, and GUTS HeadlinesRecent News About These CompaniesHead to Head Contrast: SeaStar Medical (NASDAQ:ICU) vs. Orchestra BioMed (NASDAQ:OBIO)May 24 at 2:11 AM | americanbankingnews.comWhat is Chardan Capital's Forecast for OBIO FY2026 Earnings?May 18, 2025 | americanbankingnews.comOrchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comOrchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative OptimismMay 14, 2025 | seekingalpha.comOrchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comOrchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical MilestonesMay 12, 2025 | globenewswire.comOrchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough DesignationMay 11, 2025 | msn.comOrchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global PatentsMay 9, 2025 | nasdaq.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%May 9, 2025 | aaii.comOrchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 8, 2025 | finance.yahoo.comBarclays Has Lowered Expectations for Orchestra BioMed (NASDAQ:OBIO) Stock PriceMay 7, 2025 | marketbeat.comOrchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 7, 2025 | globenewswire.comOrchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 5, 2025 | zacks.comBoxer Capital Management LLC Makes New $953,000 Investment in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)May 4, 2025 | marketbeat.comOrchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR TreatmentMay 1, 2025 | msn.comOrchestra BioMed to Present at Jefferies Global Healthcare ConferenceMay 1, 2025 | msn.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%May 1, 2025 | aaii.comFDA approves head-to-head trial of Orchestra BioMed’s balloonApril 30, 2025 | investing.comOrchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% - Time to Sell?April 30, 2025 | marketbeat.comOrchestra BioMed wins FDA IDE for sirolimus-angioballoonApril 29, 2025 | massdevice.comOrchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated BalloonApril 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFEMY, OBIO, ICAD, and GUTS Company DescriptionsFemasys NASDAQ:FEMY$1.04 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.02 -0.02 (-1.92%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Fractyl Health NASDAQ:GUTS$1.95 +0.15 (+8.33%) Closing price 04:00 PM EasternExtended Trading$1.90 -0.04 (-2.31%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.iCAD NASDAQ:ICAD$3.79 +0.06 (+1.61%) Closing price 04:00 PM EasternExtended Trading$3.79 0.00 (0.00%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.Orchestra BioMed NASDAQ:OBIO$2.82 +0.10 (+3.68%) Closing price 04:00 PM EasternExtended Trading$2.82 +0.01 (+0.18%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
